Nikhil Lalwani - 12 Feb 2026 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)

Role
PRESIDENT & CEO, Director
Signature
/s/ Nikhil Lalwani, by attorney-in-fact Meredith W. Cook
Issuer symbol
ANIP
Transactions as of
12 Feb 2026
Net transactions value
-$1,693,123
Form type
4
Filing time
17 Feb 2026, 16:07:19 UTC
Previous filing
13 Feb 2026
Next filing
02 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lalwani Nikhil PRESIDENT & CEO, Director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE /s/ Nikhil Lalwani, by attorney-in-fact Meredith W. Cook 17 Feb 2026 0001822629

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIP Common Stock Tax liability $896,470 -11,688 -3.1% $76.70 368,872 12 Feb 2026 Direct F1
transaction ANIP Common Stock Tax liability $796,653 -10,298 -2.8% $77.36 358,574 14 Feb 2026 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 22,849 shares of restricted stock, the grant of which was previously reported on February 18, 2025.
F2 Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 20,132 shares of restricted stock, the grant of which was previously reported on February 16, 2024.